Takeda Pharmaceutical Company Limited Other Comprehensive Income Before Tax Exchange Differences On Translation
Takeda Pharmaceutical Company Limited (TAK) reported Other Comprehensive Income Before Tax Exchange Differences On Translation of -JPY 153.79 billion for the 12-month period ending 2025-03-31, per its 20-F filed 2025-06-25.
Financial Statements › Income Statement › Unrealized Gains
ifrs-full:OtherComprehensiveIncomeBeforeTaxExchangeDifferencesOnTranslation · last filed 2025-06-25
| Period end | Other Comprehensive Income Before Tax Exchange Differences On Translation 12 month | Other Comprehensive Income Before Tax Exchange Differences On Translation 12 month as first filed |
|---|---|---|
| 2025-03-31 | -153.79B JPY 20-F · filed 2025-06-25 | |
| 2024-03-31 | 956.25B JPY 20-F · filed 2025-06-25 | |
| 2023-03-31 | 566.68B JPY 20-F · filed 2025-06-25 | |
| 2022-03-31 | 558.10B JPY 20-F · filed 2024-06-26 | |
| 2021-03-31 | 284.24B JPY 20-F · filed 2023-06-28 | |
| 2020-03-31 | -189.79B JPY 20-F · filed 2022-06-29 | |
| 2019-03-31 | 36.14B JPY 20-F · filed 2021-06-29 | 39.80B JPY 20-F · filed 2019-06-27 |
| 2018-03-31 | 48.09B JPY 20-F · filed 2020-06-24 | |
| 2017-03-31 | -51.23B JPY 20-F · filed 2019-06-27 |